Market Snapshot

BSE Sensex: 74570.36 1.14%
BSE 500: 33100.21 0.68%
BSE 200: 10355.93 0.78%
BSE 100: 23748.13 0.83%
BSE Mid-Cap: 41870.14 0.68%
BSE Small-Cap: 47301.56 0.13%
BANKEX: 55983.45 2.52%
BSE IT Sector: 34427.54 0.02%
Nifty 50: 22617.4 0.88%
Nifty 500: 20971.3 0.63%
Nifty 200: 12660.75 0.72%
Nifty 100: 23414.95 0.79%
Nifty Midcap 100: 50801.85 0.35%
Nifty Small 100: 17015.95 0.20%
Nifty IT: 33574.95 -0.27%
Nifty PSU Bank: 7562.9 2.48%

News:

Gland Pharma gets US FDA nod f...
Central Bank of India rises fo...
UCO Bank soars 2.02%...
Lupin Ltd gains for third cons...
Aurobindo Pharma Ltd rises for...

Windlas Biotech Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

Invest

29 Apr 2024 | 02:37 PM

552.00

5.80 (1.06%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Outperforms Index

117.45%

Return (1Y)

Beaten S&P BSE Sensex by 95.18%
More Volatile

2.88%

Standard Deviation (1Y)

Higher than S&P BSE Sensex by 2.25%
Consistent Performer

7/12

Months

beaten S&P BSE Sensex
AxisDirect View

No View

52 Week High-Low

590

249

News & Announcements

Windlas Biotech commissions its injectable facility
27 days ago

Windlas Biotech commissions its injectable facility

02 - Apr - 2024 12:00 AM | 27 days ago

Windlas Biotech announced the commissioning of its state-of-the-art injectable facility for manufacturing of Small Volume Parenteral products, built to meet international cGMP standards.
The Company has received manufacturing license from the Drug Controlling & Licensing Authority of Uttarakhand after joint inspection conducted by Central Drugs Standard Control Organisation and State Licensing Authority of Uttarakhand. The facility has initiated manufacturing of commercial batches and the company expects to introduce several new products over the course of Financial Year 2025.
This milestone marks company's continued foray in development and manufacturing of complex dosage forms like Ampoules, Liquid Vials and Lyophilized Vials thereby extending its product portfolio to critical care and other specialized therapeutic segments. This Injectable plant shall cater to all three of its business verticals: CDMO, Trade Generics & Institutional, and Exports.
Powered by Capital Market - Live News
Windlas Biotech consolidated net profit rises 64.31% in the December 2023 quarter
80 days ago

Windlas Biotech consolidated net profit rises 64.31% in the December 2023 quarter

08 - Feb - 2024 12:00 AM | 80 days ago

Net profit of Windlas Biotech rose 64.31% to Rs 15.10 crore in the quarter ended December 2023 as against Rs 9.19 crore during the previous quarter ended December 2022. Sales rose 35.51% to Rs 162.21 crore in the quarter ended December 2023 as against Rs 119.70 crore during the previous quarter ended December 2022.
Particulars Quarter Ended
Dec. 2023 Dec. 2022 % Var.
Sales 162.21 119.70 36
OPM % 12.54 11.65 -
PBDT 23.20 15.95 45
PBT 19.81 12.82 55
NP 15.10 9.19 64
Powered by Capital Market - Live News
Windlas Biotech schedules board meeting
88 days ago

Windlas Biotech schedules board meeting

01 - Feb - 2024 12:00 AM | 88 days ago

Windlas Biotech will hold a meeting of the Board of Directors of the Company on 8 February 2024.
Powered by Capital Market - Live News
Windlas Biotech consolidated net profit rises 15.09% in the September 2023 quarter
172 days ago

Windlas Biotech consolidated net profit rises 15.09% in the September 2023 quarter

08 - Nov - 2023 12:00 AM | 172 days ago

Net profit of Windlas Biotech rose 15.09% to Rs 14.03 crore in the quarter ended September 2023 as against Rs 12.19 crore during the previous quarter ended September 2022. Sales rose 15.02% to Rs 152.67 crore in the quarter ended September 2023 as against Rs 132.73 crore during the previous quarter ended September 2022.
Particulars Quarter Ended
Sep. 2023 Sep. 2022 % Var.
Sales 152.67 132.73 15
OPM % 12.24 12.09 -
PBDT 21.64 18.54 17
PBT 18.31 15.64 17
NP 14.03 12.19 15
Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

Windlas Biotech Ltd is trading very close to its All time High
Windlas Biotech Ltd is trading very close to its 52 Week High
FII shareholding in Windlas Biotech Ltd has decreased by -13.09% since past 3 Months
FII shareholding in Windlas Biotech Ltd has decreased by -5.04% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

Particulars	Quarter Ended
	Dec. 2023	Dec. 2022	% Var.
Sales	162.21	119.70	36
OPM %	12.54	11.65	-
PBDT	23.20	15.95	45
PBT	19.81	12.82	55
NP	15.10	9.19	64

Particulars	Quarter Ended
	Sep. 2023	Sep. 2022	% Var.
Sales	152.67	132.73	15
OPM %	12.24	12.09	-
PBDT	21.64	18.54	17
PBT	18.31	15.64	17
NP	14.03	12.19	15

General Notifications

My Notifications

Research Notifications

Windlas Biotech Ltd Share Price – NSE / BSE Pharmaceuticals, Small Cap

552.00 5.80 (1.06%)

News & Announcements

Price vs Volume

Stock Trivia

Windlas Biotech Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

552.00

5.80 (1.06%)